PARIS Sanofi and Regeneron Pharmaceuticals said their Zaltrap drug candidate failed to meet targets in a late-stage study for the treatment of prostate cancer, though U.S. authorities were reviewing it for use in treating colon cancer.
Regeneron had said in December that Sanofi had withdrawn its application for marketing approval for Zaltrap and was planning to resubmit it early this year.
"The study did not meet the pre-specified criterion of improvement in overall survival," Sanofi said, referring to a Phase III study of Zaltrap, also known as aflibercept, in treating prostate cancer.
Sanofi added in a statement on Thursday that the U.S. Food and Drug Administration had granted a priority review to the companies to examine Zaltrap in the treatment of colon cancer. The FDA is due to give a decision by August 4.
Priority review is granted to a drug if preliminary estimates show it has the potential to provide a treatment where no adequate therapy exists or a significant improvement compared with marketed products, Sanofi said.
"Sanofi and Regeneron are committed to the continued development of Zaltrap," Sanofi oncology head Debasish Roychowdhury said in the statement.
(Reporting by Nina Sovich; Editing by James Regan)
Trending On Reuters
The World Health Organization on Thursday recommended a speedier, cheaper treatment plan for patients with superbug forms of tuberculosis (TB) - a change that should help cure thousands of the killer disease. Full Article
- Smoking ban weakly linked to decline in preterm births
- Death after surgery three times more likely in lower-income countries
- Abortion rates fall to historic low in wealthy countries, little changed elsewhere
- Mosquito-repellent soap invention seeks to wash away Africa malaria threat
- Brazil says Zika-linked microcephaly cases fall to 4,759